GlassScriptPhysician profile
Walter G Griffith
NPI 1780792374
$10,157.85
in general payments reported to CMS, 2019-2025
29 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,507 · 2020: $1,142 · 2021: $458 · 2022: $1,044 · 2023: $1,811 · 2024: $2,004 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,007.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $2,213.91 | 2019-2022 | |
| Abbvie INC. | $1,499.38 | 2021-2025 | |
| Axsome Therapeutics, INC. | $824.74 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $584.37 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $531.64 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $523.63 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $489.14 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $484.70 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $385.72 | 2022-2025 | Lybalvi, Aristada |
| Livanova USA, INC. | $325.55 | 2020-2021 | |
| Allergan, INC. | $325.41 | 2019-2020 | |
| Lundbeck LLC | $230.29 | 2021-2025 | Rexulti |
| Eisai INC. | $186.77 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $166.64 | 2019-2020 | |
| Almatica Pharma LLC | $165.25 | 2023-2024 | Loreev Xr, Sertraline Hcl |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $152.34 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $142.53 | 2019-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $138.93 | 2024-2025 | Xelstrym |
| Corium, LLC | $128.10 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $117.43 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $99.29 | 2023-2024 | Trintellix |
| Lilly USA, LLC | $96.72 | 2019 | |
| Tris Pharma INC | $86.39 | 2022-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $42.61 | 2021-2025 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $32.66 | 2022 | |
| Bausch Health US, LLC | $24.53 | 2025 | Aplenzin |
| Noven Pharmaceuticals, INC. | $19.02 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $18.32 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.